Less toxic treatment options for patients with myeloperoxidase (MPO)-ANCAassociated GN are needed. Using an established murine model of focal necrotizing GN mediated by autoimmunity to MPO (autoimmune anti-MPO GN), we assessed the capacity for nasal tolerance induced by nasal insufflation of the immunodominant nephritogenic MPO peptide established anti-MPO autoimmunity attenuated the subsequent development of GN, confirming that the immunosuppression induced by these T cells is antigen specific. Ex vivo studies showed that nasal tolerance to MPO is mediated by both conventional and induced T regulatory cells. The strong homology between the pathogenic human MPO B cell epitope recognized by ANCA in patients with acute vasculitis and the nephritogenic murine T cell MPO epitope emphasizes the clinical relevance of this study.
ANCA-associated GN is the most common form of crescentic GN. Among patients with ANCA-associated GN, most have ANCA that reacts to myeloperoxidase (MPO). MPO, the major constituent of the azurophilic granules in neutrophils, is a heme-containing enzyme that plays a key role in the generation of injurious oxidant products. These products are potent antimicrobial agents 1 but can also mediate tissue injury in GN. 2 Cyclophosphamide is still the standard of care for patients with MPO-ANCA-associated GN. 3 This drug has adverse side effects, including severe and life-threatening infections, sterility, acute myeloid leukemia, bladder cancer, and hemorrhagic cystitis. [4] [5] [6] New, more targeted, less toxic therapies are needed. Experimental animal models have provided a depth of understanding of the pathogenesis of MPO-ANCAassociated GN. This disease begins with the loss of tolerance and development of autoimmunity to MPO. In 2012, the dominant disease-inducing murine MPO epitope, MPO 409-428 , was defined 7 and shown to have high homology with the immunodominant human MPO B cell epitope recognized by sera from patients with active MPO-ANCA-associated GN. 8 Discovery of an immunodominant nephritogenic MPO peptide offers the opportunity for thedevelopmentofpeptidebased immunomodulatory therapies that may provide antigen-specific immunosuppression capable of restoring immune homeostasis with antigenic specificity. 9 Mucosal tolerance is a phenomenon, whereby peripheral tolerance is maintained by administering the antigen of interest through the oral or nasal/respiratory routes. [10] [11] [12] The induction of tolerance by mucosal administration of autoantigens or immunodominant/immunogenic peptides has been reported in various experimental models of autoimmune diseases, including encephalomyelitis, 13,14 myasthenia gravis, 15, 16 uveitis, 16, 17 diabetes, [18] [19] [20] arthritis, [21] [22] [23] and autoimmune GN. 24, 25 In several of these studies, nasal administration of the immunodominant peptide was more effective in inducing tolerance than oral peptide administration. 22, 23, 25, 26 Despite considerable research in this area, the mechanisms involved in the induction of mucosal tolerance are uncertain.
In these studies, we examined the effects of nasal administration of the mouse immunodominant MPO T cell peptide (mouse sequence numbering MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] ; mapped to the heavy-chain region of the MPO molecule) in the prevention and treatment of GN in experimental autoimmune anti-MPO GN. 8 Induction of mucosal tolerance is dependent on the dose of antigen administered. In some experimental models of autoimmune diseases, administration of high-dose peptide is more effective to treat established disease by favoring the induction of clonal anergy or deletion. Low-dose therapy prevents the development of autoimmunity by generating a subset of regulatory T cells (Tregs) inducing immunoregulation through their production of IL-10, TGF-b, and IL-4. 10, 11 To determine the optimal dosage of MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] in nasal tolerance induction in experimental autoimmune anti-MPO GN, we administered different dosages of MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] (cumulative dose of 3, 30, or 150 mg divided over three consecutive daily administrations; days 23, 22, and 21) by nasal insufflation before the induction of anti-MPO T cell autoimmunity by subcutaneous MPO immunization (day 0). Nasal insufflation of 150 mg MPO 409-428 effectively limited the development of anti-MPO T cell autoimmunity compared with the effect of lower dosages of MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] (cumulative dose of 3 or 30 mg), which were assessed by the frequency of MPO 409-428 or whole-MPOspecific IFN-g-and IL-17A-producing lymph node (LN) cells draining the immunization site (Supplemental Figure 1,  A and B) .
Having determined the optimal dose of MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] in nasal tolerance, the potential of nasal administration of MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] Figure 1A ) as well as the frequency of IFN-g-and IL-17A-producing cells ( Figure 1 , B and C). Furthermore, nasal insufflation of MPO 409-428 decreased circulating MPO-ANCA IgG titers ( Figure 1D ). Collectively, these results indicate that nasal administration of The mechanisms involved in the development of mucosal tolerance to autoantigens are not well understood. It has been previously shown that nasal tolerance induces antigen-specific Tregs in a model of delayed type hypersensitivity responses to OVA as a foreign antigen and that CD4 + T cell transfer from OVA-tolerized mice can prevent the development of delayed type hypersensitivity to OVA in recipient mice. 27 To define mechanisms by which nasal administration of MPO 409-428 may prevent anti- + T cells did not attenuate GN, and disease severity was similar to control mice that did not receive cells (Supplemental Figure 2) .
In conclusion, this study reveals that re-establishing tolerance to MPO with the immunodominant MPO peptide by the nasal route allows for antigen-specific immunomodulation. The successful induction of tolerance to MPO peptide justifies future studies of the mechanisms of how nasal mucosal-associated lymphoid tissue induces tolerance. Relevant to these studies is the high-degree of homology of this nephritogenic peptide with the dominant human MPO peptide found in studies of sera from patients with acute MPO-ANCA-associated vasculitis. This discovery provides proof of concept to underpin preclinical studies to assess whether peptide-induced nasal tolerance may be therapeutic in patients with MPO-ANCA-associated GN.
CONCISE METHODS

Mice and Experimental Design
Eight-to twelve-week-old male C57BL/6 (wild type) and Foxp3-GFP mice (from Alexander Rudensky, University of Washington, Seattle, WA) were bred and housed in specific pathogen-free conditions at Monash Medical Centre Animal Facilities, Monash University. Studies were approved by the Monash University Animal Ethics Committee in accordance with the Australian National Health and Medical Research Council animal experimentation guidelines.
Peptides MPO 409-428 (PRWNGEKLY-QEARKIVGAMV) and the control irrelevant immunodominant OVA peptide (OVA 323-339 ; ISQAVHAAHAEINEAGR) were synthesized by Mimotopes Australia. To determine the optimal dose of intranasal MPO 409-428 , three groups of mice (n=4) were given MPO 409-428 in 20 ml saline nasally on 3 consecutive days (days 23, 22, and 21) with total cumulative doses of 3, 30, and 150 mg. Control mice received 20 ml saline nasally (n=4). On day 0, mice were immunized with 25 mg MPO 409-428 in Freund's Complete Adjuvant subcutaneously at the base of tail, and they were killed on day 10. Draining LNs from MPO immunization sites were aseptically removed for analysis of systemic immunity.
For prevention of experimental anti-MPO GN, 150 mg MPO 409-428 or OVA 323-339 in 20 ml saline was administered nasally for 3 consecutive days. Mice were then immunized on day 0 with 100 mg MPO 409-428 in Freund's Complete Adjuvant subcutaneously at the base of tail, and on day 7, they were immunized with 100 mg MPO 409- 
